70280-03-4

Basic information

• Product Name: N-ACETYL-D-GLUCOSAMINYL-(BETA1,4)-N-ACETYLMURAMYL-L-ALANYL-D-ISOGLUTAMINE
• Synonyms: d-alpha-glutamine,n-(n-acetyl-4-o-(2-(acetylamino)-2-deoxy-beta-d-glucopyrano;glucosaminylmuramyldipeptide;n-acetyl-beta-glucosaminyl-(1-4)-n-acetylmuramyl-l-alanyl-d-isoglutamine;n-acetyl-beta-glucosaminyl-n-acetylmuramyl-alanylisoglutamine;n-acetylglucosaminyl-n-acetylmuramyl-l-alanyl-d-isoglutamine;syl)muramoyl)-l-alanyl-;4-(2-ACETAMIDO-2-DEOXY-BETA-D-GLUCOPYRANOSYL)-N-ACETYLMURAMYL-L-ALA-D-GLU AMIDE;D-GLCNAC-BETA-(1->4)-N-ACETYLMURAMYL-L-ALA-D-ISOGLUTAMINE
• CAS NO: 70280-03-4
• Molecular Formula: C27H45N5O16
• Molecular Weight: 695.67
• Mol File: 70280-03-4.mol
• Article Data: 0

Chemical Properties

• Boiling Point: 1270.1°Cat760mmHg
• Flash Point: 721.9°C
• Appearance: /
• Density: 1.47g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.587
• Storage Temp.: −20°C
• CAS DataBase Reference: N-ACETYL-D-GLUCOSAMINYL-(BETA1,4)-N-ACETYLMURAMYL-L-ALANYL-D-ISOGLUTAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: N-ACETYL-D-GLUCOSAMINYL-(BETA1,4)-N-ACETYLMURAMYL-L-ALANYL-D-ISOGLUTAMINE(70280-03-4)
• EPA Substance Registry System: N-ACETYL-D-GLUCOSAMINYL-(BETA1,4)-N-ACETYLMURAMYL-L-ALANYL-D-ISOGLUTAMINE(70280-03-4)

Safety Data

• Hazard Codes: Xn
• Statements: 20/21/22
• Safety Statements: 36/37
• WGK Germany: 3
• RTECS: MA2275230
• Hazardous Substances Data: 70280-03-4(Hazardous Substances Data)

Usage

Description

N-acetyl-β-D-glucosaminyl-( 1→4)-N-acetylmuramyl-L-alanyl-D-isoglutamine was launched in Russia for hospital-related infections, psoriasis, cervical precancerous lesions and ophthalmic keratitis caused by herpes. It was found to be less pyrogenic than MDP, the minimally active component of Freund's complete adjuvant. While chemical synthesis is possible, a less laborious method (3 steps) involves the enzymatic degradation of a bacterial peptidoglycan. GDMP is orally active with a low toxicity that acts as an adjuvant to highly purified protein antigens to stimulate the induction of CD8* T-cell response. It was also able to reduce the levels of TNF-α, IL-1α and hypoglycemia induced by LPS administration and to inhibit systemic response to endotoxin.

Originator

Peptech (Australia)

Uses

N-?Acetyl-?β-?D-?glucosaminyl-?N-?acetylmuramyl-?L-?alanyl-?D-?isoglutamine acts as an immunnomodulator or immunostimulant in the treatment of various auto-immune diseases.

Brand name

Likopid

InChI:InChI=1/C27H45N5O16/c1-10(25(44)32-14(24(28)43)5-6-18(39)40)29-26(45)11(2)46-22(15(7-33)30-12(3)36)23(16(38)8-34)48-27-19(31-13(4)37)21(42)20(41)17(9-35)47-27/h7,10-11,14-17,19-23,27,34-35,38,41-42H,5-6,8-9H2,1-4H3,(H2,28,43)(H,29,45)(H,30,36)(H,31,37)(H,32,44)(H,39,40)/t10-,11+,14+,15-,16+,17+,19+,20+,21+,22+,23+,27-/m0/s1